文献速递主动脉疾病

主动脉食管瘘:致命连接的修复——系统综述与荟萃分析

Aortoesophageal Fistula: Mending the Lethal Connection-A Systematic Review and Meta-Analysis.
PubMed 文献 · Ann Vasc Surg · 2026-06-25

该系统综述与荟萃分析纳入167篇报告共528例主动脉食管瘘患者,评估不同治疗策略的生存与并发症结局。总体30天死亡率为31.2%,1年死亡率为41.2%。分阶段TEVAR后手术生存较好但感染和再干预率高,形态学严重程度与死亡强相关,推荐基于形态学的个体化管理。

要点

  • 主动脉食管瘘总体30天死亡率31.2%,1年死亡率41.2%。
  • 分阶段TEVAR后手术30天死亡率12.7%、1年死亡率26.1%,但感染率66.7%。
  • 形态学严重程度与死亡、感染、再干预和复发强相关,IV型预后尤其差。

核心结论

  • 尽管采用现代管理,主动脉食管瘘仍具有高早期和晚期死亡率。
  • 确定性策略尤其是分阶段TEVAR后手术可改善生存但增加并发症。
  • 推荐基于形态学的个体化管理。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed和Scopus截至2025年12月。
  • 共纳入167篇报告,代表528例患者。
  • 按治疗策略分为5组:单纯TEVAR、分阶段TEVAR后手术、初次开放或杂交手术、TEVAR联合食管支架、支持/姑息治疗。
  • 结局以比例及95%置信区间(CI)合并。

主要发现

  • 总体30天死亡率为31.2%(95% CI 27.0%至35.7%),1年死亡率为41.2%(95% CI 36.2%至46.4%)。
  • 感染发生率为32.6%,再干预率为20.2%,复发率为13.2%。
  • 分阶段TEVAR后手术30天死亡率12.7%、1年死亡率26.1%,但感染率66.7%、再干预率43.2%。
  • TEVAR联合食管支架早期死亡率最低(5.0%),但再干预频繁(54.5%),1年死亡率33.3%。
  • 单纯TEVAR在确定性策略中1年死亡率最低(25.5%),但复发率26.9%。

临床怎么用

  • 临床决策应结合形态学严重程度个体化选择治疗策略。
  • 分阶段TEVAR后手术可考虑用于追求生存获益,但需警惕高感染和再干预风险。
  • TEVAR联合食管支架早期死亡率低但再干预频繁,需权衡。
  • 单纯TEVAR需注意复发风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aortoesophageal fistula (AEF) is a rare, life-threatening condition with limited high-quality evidence to guide management. METHODS: We conducted a systematic review and meta-analysis of PubMed and Scopus through December 2025, evaluating survival and complication outcomes according to treatment strategy and morphological severity. Patients were categorized into 5 groups: TEVAR alone, staged TEVAR followed by surgery, primary open or hybrid surgery, TEVAR with esophageal stenting, and supportive/palliative care. Outcomes were pooled as proportions with 95% confidence intervals (CIs). RESULTS: A total of 167 reports representing 528 patients were included. Overall 30-day mortality was 31.2% (95% CI 27.0% to 35.7%) and 1-year mortality 41.2% (95% CI 36.2% to 46.4%). Infection occurred in 32.6%, reintervention in 20.2%, and recurrence in 13.2%. Staged TEVAR followed by surgery showed favorable survival (30-day 12.7%, 1-year 26.1%) but high infection (66.7%) and reintervention (43.2%) rates. TEVAR with esophageal stenting had the lowest early mortality (5.0%) but frequent reintervention (54.5%) and 1-year mortality of 33.3%. TEVAR alone demonstrated the lowest 1-year mortality among definitive strategies (25.5%) but notable recurrence (26.9%). Primary open or hybrid surgery carried higher early and late mortality, while supportive/palliative care had the worst outcomes. Morphological severity correlated strongly with mortality, infection, reintervention, and recurrence, with type IV lesions showing particularly poor prognosis. CONCLUSION: Despite contemporary management, AEF carries high early and late mortality. Definitive strategies, particularly staged TEVAR followed by surgery, offer improved survival but increased complications. Morphology-guided, individualized management is recommended.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Hantash NA, El Beyrouti H, Alghzawi Y, et al. Aortoesophageal Fistula: Mending the Lethal Connection-A Systematic Review and Meta-Analysis. Ann Vasc Surg. 2026. PMID: 42349639. doi:10.1016/j.avsg.2026.06.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。